Amneal has taken a major step to further expand its business outside of its home US market by striking a “long-term license agreement” with Finland’s Orion to market “a number of Amneal’s complex generic products” in Europe, Australia and New Zealand.
Amneal Reveals Orion As European Partner
Collaboration With Finnish Firm Also Covers Australia And New Zealand
Amneal has delivered on promises that it would soon finalize a European partnership by announcing a long-term licensing collaboration with Finnish firm Orion that will also cover Australia and New Zealand.
More from Deals
More from Business
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.